RJA
ONXX

Raymond James & Associates’s ONYX PHARMACEUTICALS INC ONXX Stock Holding History

Raymond James & Associates’s Portfolio ONXX Stock Details ONXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-27,749
Closed -$2.41M – 2046
2013
Q2 		$2.41M Buy
+27,749
New +$2.55M 0.02% 718

Other funds holding ONXX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James & Associates's ONXX Position: Q3 2013 in Review

Raymond James & Associates sold out of ONYX PHARMACEUTICALS INC (ONXX) in Q3 2013, closing a stake of 27,749 shares — an estimated $2.41M sold.

Raymond James & Associates first reported a position in ONXX in Q2 2013 and held it in 1 quarter. The position peaked at $2.41M in Q2 2013. 258 funds tracked by Wall St. Rank hold ONXX as of Q3 2013.

  • Raymond James & Associates reported no remaining ONYX PHARMACEUTICALS INC position as of Q3 2013 after selling out during the quarter.
  • Raymond James & Associates sold 27,749 ONYX PHARMACEUTICALS INC shares in Q3 2013, an estimated $2.41M.
  • Raymond James & Associates first reported a position in ONYX PHARMACEUTICALS INC in Q2 2013 and held it in 1 quarter.
  • Raymond James & Associates's ONYX PHARMACEUTICALS INC position peaked at $2.41M in Q2 2013.
  • 258 funds tracked by Wall St. Rank held ONYX PHARMACEUTICALS INC as of Q3 2013.

Based on Raymond James & Associates's 13F filing for Q3 2013, filed 13 Nov 2013.